Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Issues
2013
March 2013, Highlights
March 2013, Highlights
New Meta-Analysis: Complete Response to Neoadjuvant Therapy in Breast Cancer Predictor of Long-Term Benefit
By
Audrey Andrews
Clinical Research
,
Personalized Medicine
March 2013, Highlights
A new meta-analysis confirmed that patients with breast cancer who achieve a pathologic complete response (pCR) to neoadjuvant therapy have a more favorable outcome than those who do not.
Read Article
Evidence Still Cloudy for Anticancer Effects with Metformin
By
Caroline Helwick
Clinical Research
,
Personalized Medicine
March 2013, Highlights
Observational studies have suggested that the antidiabetes agent metformin (Glucophage) may have anticancer effects. New studies have attempted to confirm this, but the results and their meaning still remain unclear.
Read Article
More Evidence Links Vitamin D Deficiency to Worse Outcomes in Breast Cancer
By
Caroline Helwick
Clinical Research
,
Personalized Medicine
March 2013, Highlights
More evidence is accumulating that vitamin D levels play a role in breast cancer outcomes. Investigators from the United Kingdom reported that postmenopausal women with sufficient vitamin D levels were significantly less likely to develop bone metastases when taking zoledronic acid (Zometa) compared with women with lower vitamin D levels.
Read Article
Venlafaxine Lowers Endoxifen Levels, Reduces Tamoxifen Effectiveness
By
Caroline Helwick
Clinical Research
,
Personalized Medicine
March 2013, Highlights
The antidepressant venlafaxine (Effexor) is often prescribed to patients with breast cancer who are taking tamoxifen (Nolvadex) to help reduce the side effect of hot flashes. But according to research presented at the meeting, venlafaxine may reduce the effectiveness of tamoxifen.
Read Article
HDAC Inhibitor plus PARP Inhibitor or Cisplatin Induce Apoptosis of Triple-Negative Breast Cancer Cells
By
Caroline Helwick
Breast Cancer
,
Personalized Medicine
,
Solid Tumors
March 2013, Highlights
Histone deacetylase (HDAC) inhibitors may have a future in the targeted treatment of triple-negative breast cancer, if the results of in vitro studies can be replicated clinically.
Read Article
Benefit of Higher Doses of Fulvestrant Confirmed
By
Caroline Helwick
Hormone Therapy
,
Personalized Medicine
March 2013, Highlights
Although many clinicians are already prescribing fulvestrant (Faslodex) at a dose of 500 mg, a phase 3 study presented at the meeting confirmed the superiority of this dose over 250 mg.
Read Article
Letrozole Superior to Tamoxifen for a Subtype of Breast Cancer
By
Audrey Andrews
Hormone Therapy
,
Personalized Medicine
March 2013, Highlights
A comparison of letrozole (Femara) with tamoxifen (Nolvadex) demonstrated that the former may be superior for the treatment of postmenopausal estrogen receptor (ER)-positive patients who have lobular carcinoma, according to a subanalysis of patients in the phase 3 BIG 1-98 trial.
Read Article
Black Women Less Likely to Receive Sentinel Node Dissection Therapy
By
Caroline Helwick
Sentinel Node Management
,
Personalized Medicine
March 2013, Highlights
Black women and other racial minorities are less likely than white women to receive sentinel lymph node (SLN) dissection as the standard of care for clinically node-negative breast cancer, and this has negative consequences, an analysis of the Surveillance, Epidemiology and End Results (SEER)/Medicare database suggested.
Read Article
Sentinel Node Surgery Correctly Stages Lymph Nodes Following Neoadjuvant Chemotherapy
By
Audrey Andrews
Sentinel Node Management
,
Personalized Medicine
March 2013, Highlights
Axillary lymph node dissection (ALND) may not be necessary after neoadjuvant chemotherapy in most patients, according to investigators who found that sentinel lymph node (SLN) dissection correctly staged more than 90% of patients.
Read Article
Molecular Profiling in Early Invasive Breast Cancer
By
Caroline Helwick
Prognostic Tests
,
Personalized Medicine
March 2013, Highlights
In making decisions about adjuvant chemotherapy, biologic subtype has replaced nodal status and tumor size as parameters to consider, although subtype—and tests that define them—are still insufficient for the provision of optimal care, said Antonio C. Wolff, MD, Professor of Oncology at Johns Hopkins University School of Medicine, Baltimore.
Read Article
Page 1 of 3
1
2
3
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Navigating the Complex Landscape of Oral Cancer Medication
2.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
3.
New NCCN Guidelines for CLL/SLL Include Second-Generation BTK Inhibitors
Wayne Kuznar
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma